Pharmaco-economic issues for diabetes therapy

Bottomley, Julia M.; Raymond, Frank D.

doi:10.1016/j.beem.2007.08.002

Cited by 28 publications

(17 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lifestyle interventions, such as changes in diet and exercise, and medications are essential in reducing the risk for development of complications. Thanks to improved management, the prevalence of diabetic complications is constantly decreasing, but these improved clinical outcomes came with a cost of £708 million per year in the UK, corresponding to 7 % of the UK health-care prescribing budget [ 2 ]. Nevertheless, once cardiovascular complications occur, these are more difficult to treat in patients with DM as compared with patients without DM.…”

Section: Introductionmentioning

confidence: 99%

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Mangialardi

Madeddu

2016

Curr Diab Rep

View full text Add to dashboard Cite

Diabetes is one of the main economic burdens in health care, which threatens to worsen dramatically if prevalence forecasts are correct. What makes diabetes harmful is the multi-organ distribution of its microvascular and macrovascular complications. Regenerative medicine with cellular therapy could be the dam against life-threatening or life-altering complications. Bone marrow-derived stem cells are putative candidates to achieve this goal. Unfortunately, the bone marrow itself is affected by diabetes, as it can develop a microangiopathy and neuropathy similar to other body tissues. Neuropathy leads to impaired stem cell mobilization from marrow, the so-called mobilopathy. Here, we review the role of bone marrow-derived stem cells in diabetes: how they are affected by compromised bone marrow integrity, how they contribute to other diabetic complications, and how they can be used as a treatment for these. Eventually, we suggest new tactics to optimize stem cell therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Mangialardi

Madeddu

2016

Curr Diab Rep

View full text Add to dashboard Cite

show abstract

“…However, further analysis is warranted to provide more robust data on the comparative risk of the different types of hypoglycaemia at different times of day, taking into account the insulin regimen used to inform clinicians and to help people with T2DM in making choices between insulins. Results are also needed to feed into health economic models assessing the cost-effectiveness of the new insulins [20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Meta‐analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine

Home

Fritsche

Schinzel

et al. 2010

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…For example, the generally accepted ICER thresholds in the USA, Western Europe and the UK, respectively, are US$50,000/QALY [19], €50,000/QALY [20] (equivalent to approximately US$73,348/QALY ) and GBP£20-30,000/QALY [21] (~US$32,884-49,325/QALY). Such analyses are increasingly important in the current era of soaring medical costs and healthcare budgets under pressure.…”

Section: Suh and Aagrenmentioning

confidence: 99%

“…The primary MEDLINE literature search identified 28 potentially relevant papers [20,. Of these, 13 studies [23,[25][26][27]29,31,33,34,37,44,45,48,49] fulfilled the inclusion criteria, eight were reviews or commentaries [20,36,39,[41][42][43]46,47], two were not about IDet [35,40], three were not in English [24,35,38] and one did not include costs, only insulin consumption [30].…”

Section: Search Findingsmentioning

confidence: 99%

Cost–effectiveness of insulin detemir: a systematic review

Suh

Aagren

2011

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

The prevalence of diabetes and cost of associated treatment are steadily increasing, as is the resulting burden on healthcare systems worldwide. Current treatment recommendations for Type 1 and Type 2 diabetes advise a prominent role for basal insulin. We examined the published health-economic literature pertaining to the basal insulin analog insulin detemir (IDet) to determine whether IDet is a cost-saving and/or cost-effective treatment for suboptimally controlled Type 1 or Type 2 diabetes. A total of 15 modeling studies were assessed, most of which found IDet to be cost effective compared with neutral protamine Hagedorn and as cost effective as insulin glargine. Those that did not find IDet to be cost effective set the disutility of hypoglycemic events to almost zero or assumed a higher dose of IDet with no difference in treatment effect, ignoring the clinical benefits and cost savings associated with IDet in studies demonstrating comparable or superior glycemic control with less hypoglycemia versus other basal insulins. The evidence suggests that IDet is cost effective versus neutral protamine Hagedorn and at least as cost effective as insulin glargine in the treatment of patients with suboptimally controlled Type 1 and Type 2 diabetes.

show abstract

Pharmaco-economic issues for diabetes therapy

Cited by 28 publications

References 123 publications

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications

Meta‐analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine

Cost–effectiveness of insulin detemir: a systematic review

Contact Info

Product

Resources

About